104 related articles for article (PubMed ID: 38138584)
21. Rapid and Simple Access to α-(Hetero)arylacetonitriles from
Zhang JQ; Liu J; Hu D; Song J; Zhu G; Ren H
Org Lett; 2022 Jan; 24(2):786-790. PubMed ID: 34989584
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in the syntheses of anthracene derivatives.
Baviera GS; Donate PM
Beilstein J Org Chem; 2021; 17():2028-2050. PubMed ID: 34457075
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of bis(imino)anthracene derivatives as G-quadruplex ligands.
Coban T; Robertson C; Schwikkard S; Singer R; LeGresley A
RSC Med Chem; 2021 Mar; 12(5):751-757. PubMed ID: 34124673
[TBL] [Abstract][Full Text] [Related]
24. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
Abbas HA; Wierda WG
Front Oncol; 2021; 11():668162. PubMed ID: 34055635
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.
Della Rocca AM; Leonart LP; Ferreira VL; Tonin FS; Steffenello-Durigon G; Del Moral JAG; Fernandez-Llimos F; Pontarolo R
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):514-525. PubMed ID: 33947633
[TBL] [Abstract][Full Text] [Related]
26. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
[TBL] [Abstract][Full Text] [Related]
27. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.
Skånland SS; Mato AR
Blood Adv; 2021 Jan; 5(1):334-343. PubMed ID: 33570649
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.
Lee J; Wang YL
J Mol Diagn; 2020 Sep; 22(9):1114-1125. PubMed ID: 32615167
[TBL] [Abstract][Full Text] [Related]
29. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
30. An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.
Cohen JA; Bomben R; Pozzo F; Tissino E; Härzschel A; Hartmann TN; Zucchetto A; Gattei V
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272636
[TBL] [Abstract][Full Text] [Related]
31. Precision Medicine Management of Chronic Lymphocytic Leukemia.
Moia R; Patriarca A; Schipani M; Ferri V; Favini C; Sagiraju S; Al Essa W; Gaidano G
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164276
[TBL] [Abstract][Full Text] [Related]
32. Design, Synthesis and Biochemical Evaluation of Novel Ethanoanthracenes and Related Compounds to Target Burkitt's Lymphoma.
Byrne AJ; Bright SA; McKeown JP; O'Brien JE; Twamley B; Fayne D; Williams DC; Meegan MJ
Pharmaceuticals (Basel); 2020 Jan; 13(1):. PubMed ID: 31963567
[TBL] [Abstract][Full Text] [Related]
33. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
34. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Sharman JP; Coutre SE; Furman RR; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn IW; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Tausch E; Cramer P; Huang J; Mitra S; Hallek M; O'Brien SM; Stilgenbauer S
J Clin Oncol; 2019 Jun; 37(16):1391-1402. PubMed ID: 30995176
[TBL] [Abstract][Full Text] [Related]
35. Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers.
Bright SA; Byrne AJ; Vandenberghe E; Browne PV; Mcelligott AM; Meegan MJ; Williams DC
Oncol Rep; 2019 May; 41(5):3127-3136. PubMed ID: 30896840
[TBL] [Abstract][Full Text] [Related]
36. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
37. Chronic lymphocytic leukemia treatment algorithm 2018.
Parikh SA
Blood Cancer J; 2018 Oct; 8(10):93. PubMed ID: 30283014
[TBL] [Abstract][Full Text] [Related]
38. Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs.
Shultz MD
J Med Chem; 2019 Feb; 62(4):1701-1714. PubMed ID: 30212196
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukaemia.
Hallek M; Shanafelt TD; Eichhorst B
Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
[TBL] [Abstract][Full Text] [Related]
40. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Crawford JJ; Johnson AR; Misner DL; Belmont LD; Castanedo G; Choy R; Coraggio M; Dong L; Eigenbrot C; Erickson R; Ghilardi N; Hau J; Katewa A; Kohli PB; Lee W; Lubach JW; McKenzie BS; Ortwine DF; Schutt L; Tay S; Wei B; Reif K; Liu L; Wong H; Young WB
J Med Chem; 2018 Mar; 61(6):2227-2245. PubMed ID: 29457982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
